drugset / Trial / NCT00210730
The Duration Study
Phase 3
Terminated
2 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Products, L.P. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of epoetin alfa (PROCRIT®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (PROCRIT®) treatment in patients with cancer who are anemic.
Timeline
- Start
- 2004-06
- Primary completion
- —
- Completion
- 2005-07
Outcome
Outcome not reported
Stopped (Enrollment): “This study was stopped early due to slow enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | — |